60 Degrees Pharma reports positive safety update from Phase 2 babesiosis study
- 60 Degrees Pharma (NASDAQ:SXTP) announced that an independent Data Safety Monitoring Board found no safety concerns in the first six patients in its Phase 2 B-Free chronic babesiosis study.
- The board recommended continuation of the trial testing an ARAKODA tafenoquine regimen for severe persistent fatigue.
- Tafenoquine is currently only FDA-approved for malaria prophylaxis.
60 Degrees Pharma (NASDAQ:SXTP) reported that an independent Data Safety Monitoring Board found no safety concerns in the first six patients in its Phase 2 B-Free chronic babesiosis study and recommended trial continuation.
The study tests an ARAKODA tafenoquine regimen for severe persistent fatigue.
Tafenoquine is only FDA-approved for malaria prophylaxis.
This safety update supports continued development of tafenoquine for the treatment of babesiosis.
Babesiosis is a tick-borne parasitic disease that can cause severe fatigue and other symptoms, particularly in immunocompromised patients.
60 Degrees Pharma is focused on developing therapies for infectious diseases with significant unmet medical needs.
The company continues to advance its clinical programs while exploring additional indications for tafenoquine beyond malaria prophylaxis.
More from United States
Apple Q4 revenue grows 12% to $114.5bn as earnings improve
Palantir Q3 revenue skyrockets 96% to $2.31B
Vertex Q3 revenue climbs 12% to $3.44bn as guidance increases
Oracle plans $20bn fundraising as shares fall 6.2%
Axsome Q3 loss beats estimates as revenue reaches $259.7m
Marvell to acquire Lumentum in $115bn AI deal
